Sorafenib promotes hepatocellular carcinoma invasion <i>via</i> interleukin-6/HIF-1α/PFKFB3

Zhuang, Pengyuan; Wang, Dong; Zhang, Kewei; Wang, Jiandong; Shen, Jun

doi:10.7150/jca.84451

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2023; 14(10):1859-1874. doi:10.7150/jca.84451 This issue Cite

Research Paper

Sorafenib promotes hepatocellular carcinoma invasion via interleukin-6/HIF-1α/PFKFB3

Pengyuan Zhuang^1,2,3,#, Dong Wang^1,2,3,#, Kewei Zhang⁴, Jiandong Wang^1,2,3, Jun Shen^1,2,3,✉

1. Department of General Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200092, China.
2. Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.
3. Shanghai Research Center of Biliary Tract Disease, Shanghai, 200092, China.
4. Department of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200050, China.
# Contributed equally.

Citation:

Zhuang P, Wang D, Zhang K, Wang J, Shen J. Sorafenib promotes hepatocellular carcinoma invasion via interleukin-6/HIF-1α/PFKFB3. J Cancer 2023; 14(10):1859-1874. doi:10.7150/jca.84451. https://www.jcancer.org/v14p1859.htm

Other styles

Abstract

Background: Although sorafenib is adopted as the first-line treatment for unresectable liver cancer, the antitumor efficacy is severely limited by the pro-invasive side effect.

Methods: To explore the underlying mechanisms, various-dosage sorafenib was applied to survey its effect on cell invasion in HCCLM3 and PLC cell models.

Results: Our results revealed that high-dosage sorafenib inhibited liver cancer cell invasion. By contrast, sorafenib with low and median dosages promoted the invasion. In vivo studies showed that sorafenib with a median dosage increased the intrahepatic metastasis (IHM) and lung metastasis (LM) of liver cancer cells, while sorafenib with a high dosage inhibited IHM and LM. Then, bioinformatics analysis indicated that HIF-1α, IL-6, and PFKFB3 were associated with the sorafenib resistance. In vitro models showed that the pro-invasive effect was mediated by IL-6/HIF-1α/PFKFB3 regulation in dosage- and time-dependent manners. PFKFB3 knockdown confirmed that PFKFB3 promoted HCCLM3 cell migration via modulating EMT-related markers. Furthermore, we found that sorafenib upregulated PFKFB3 by IL-6/HIF-1α in a time-dependent manner, without direct effect on PFKFB3 expression.

Conclusions: In summary, these results demonstrated that sorafenib could dose-dependently promote cell invasion, intrahepatic and lung metastasis in hepatocellular carcinoma through IL-6/HIF-1α mediated PFKFB3 activation, providing novel insights to improve the therapeutic efficacy of sorafenib.

Keywords: hepatocellular carcinoma, sorafenib, IL-6, PFKFB3, invasion

Citation styles

APA

Zhuang, P., Wang, D., Zhang, K., Wang, J., Shen, J. (2023). Sorafenib promotes hepatocellular carcinoma invasion via interleukin-6/HIF-1α/PFKFB3. Journal of Cancer, 14(10), 1859-1874. https://doi.org/10.7150/jca.84451.

ACS

Zhuang, P.; Wang, D.; Zhang, K.; Wang, J.; Shen, J. Sorafenib promotes hepatocellular carcinoma invasion via interleukin-6/HIF-1α/PFKFB3. J. Cancer 2023, 14 (10), 1859-1874. DOI: 10.7150/jca.84451.

NLM

CSE

Zhuang P, Wang D, Zhang K, Wang J, Shen J. 2023. Sorafenib promotes hepatocellular carcinoma invasion via interleukin-6/HIF-1α/PFKFB3. J Cancer. 14(10):1859-1874.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.